



[Reference Translation]

February 7, 2025

Company name: JMS Co., Ltd.  
Name of representative: Ryuji Katsura, President and Representative Director  
(Securities code: 7702; Tokyo Stock Exchange)  
Inquiries: Jo Sueda, Executive Officer, Head of Corporate Affairs Division  
(Telephone: +81-82-243-5844)

## Notice of Revision of Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2025.

In light of recent performance trends, we would like to announce the following revisions to the consolidated earnings forecast for the fiscal year ending March 2025, which was announced on November 7, 2024.

### 1. Revision of the consolidated earnings forecast for the fiscal year ending March 31, 2023 (April 1, 2024 - March 31, 2025)

(Unit: million yen)

	Net sale	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
Forecast previously announced (A)	70,000	700	400	100	4.08 yen
Forecast announced today (B)	70,000	1,000	700	250	10.21 yen
Difference (B - A)	—	300	300	150	
Difference (%)	—	42.9	75.0	150.0	
<Reference> Actual results for previous fiscal year ended March 31, 2024	65,292	(268)	145	(36)	(1.48) yen

### 2. Reasons for the revision of the earnings forecast

With regard to net sales for the first three quarters of the fiscal year ending March 2025, sales of Closed Drug Mixing/Infusion Systems, which we are focusing on as a core business, and sales of Blood Management & Cell Therapy products, which have been steadily expanding due to a recovery in overseas demand, have been generally in line with our forecasts.

In terms of profits, despite the impact of rising raw material and electricity costs, as well as increased depreciation expenses associated with capital investment, the growth of core products in Japan and overseas, and progress in passing on price increases, have resulted in profits at each stage of the income statement, from Operating profit onwards, that are slightly higher than forecast.

Based on the above-mentioned performance, we expect that the operating profit, ordinary profit, and profit attributable to owners of parent for the full fiscal year ending March 2025 will exceed the previously announced forecasts.

\*The above forecast is based on currently available information as of the announcement of this material and actual results may differ from the projected figures due to various factors.

END